Though modern available cancer therapies are effective, they possess major adverse effects,
causing non-compliance to patients. Furthermore, the majority of the polymeric-based medication
platforms are certainly not universally acceptable, due to their several restrictions. With this juxtaposition,
lipid-based medication delivery systems have appeared as promising drug nanocarriers to
replace the majority of the polymer-based products because they are in a position to reverse polymer
as well as, drug-associated restrictions. Furthermore, the amalgamation of the basic principle of
nanotechnology in designing lipid nanocarriers, which are the latest form of lipid carriers, has tremendous
chemotherapeutic possibilities as tumor-targeted drug-delivery pertaining to tumor therapy.
Apart from this, it is reported that nearly 40% of the modern medication entities are lipophilic.
Moreover, research continues to be efficient in attaining a significant understanding of the absorption
and bioavailability of the developed lipids systems.
Intracellular versus extracellular inhibition of calpain I causes differential effects on pain in a rat model of joint inflammation
